Assessing the Anti-Inflammatory Activity of the Anxiolytic Drug Buspirone Using CRISPR-Cas9 Gene Editing in LPS-Stimulated BV-2 Microglial Cells
Buspirone is an anxiolytic drug with robust serotonin receptor 1A (Htr1a) agonist activities. However, evidence has demonstrated that this drug also targets the dopamine D3 receptor (Drd3), where it acts as a potent antagonist. In vivo, Drd3 blockade is neuroprotective and reduces inflammation in mo...
Main Authors: | Sarah Thomas Broome, Teagan Fisher, Alen Faiz, Kevin A. Keay, Giuseppe Musumeci, Ghaith Al-Badri, Alessandro Castorina |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/6/1312 |
Similar Items
-
The Anxiolytic Drug Buspirone Prevents Rotenone-Induced Toxicity in a Mouse Model of Parkinson’s Disease
by: Sarah Thomas Broome, et al.
Published: (2022-02-01) -
Non-Neuronal Transmitter Systems in Bacteria, Non-Nervous Eukaryotes, and Invertebrate Embryos
by: Yuri B. Shmukler, et al.
Published: (2022-02-01) -
PACAP and VIP Modulate LPS-Induced Microglial Activation and Trigger Distinct Phenotypic Changes in Murine BV2 Microglial Cells
by: Jocelyn Karunia, et al.
Published: (2021-10-01) -
DRD2, DRD3, and HTR2A Single-Nucleotide Polymorphisms Involvement in High Treatment Resistance to Atypical Antipsychotic Drugs
by: Antonio Del Casale, et al.
Published: (2023-07-01) -
Regulation of Microglial Functions by Purinergic Mechanisms in the Healthy and Diseased CNS
by: Peter Illes, et al.
Published: (2020-04-01)